Back to Search
Start Over
Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity
- Source :
- International Immunopharmacology
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- The chemokine receptor CCR5 has been implicated in COVID-19. CCR5 and its ligands are overexpressed in patients. The pharmacological targeting of CCR5 would improve the COVID-19 severity. We sought to investigate the role of the CCR5-Δ32 variant (rs333) in COVID-19. The CCR5-Δ32 was genotyped in 801 patients (353 in the intensive care unit, ICU) and 660 healthy controls, and the deletion was significantly less frequent in hospitalysed COVID-19 than in healthy controls (p = 0.01, OR = 0.66, 95%CI = 0.49-0.88). Of note, we did not find homozygotes among the patients, compared to 1% of the controls. The CCR5 transcript was measured in leukocytes from 85 patients and 40 controls. We found a significantly higher expression of the CCR5 transcript among the patients, with significant difference when comparing the non-deletion carriers (controls = 35; patients = 81; p = 0.01). ICU-patients showed non-significantly higher expression than no-ICU cases. Our study points to CCR5 as a genetic marker for COVID-19. The pharmacological targeting of CCR5 should be a promising treatment for COVID-19.
- Subjects :
- Male
0301 basic medicine
Receptors, CCR5
Chemokine receptor CCR5
Short Communication
SARS-Cov-2
viruses
Immunology
Risk Assessment
Severity of Illness Index
03 medical and health sciences
Patient Admission
0302 clinical medicine
Risk Factors
Severity of illness
Genetic variation
Genetic susceptibility
Genetic predisposition
Humans
Immunology and Allergy
Medicine
Genetic Predisposition to Disease
Aged
Aged, 80 and over
Pharmacology
biology
business.industry
Case-control study
Genetic Variation
COVID-19
virus diseases
Middle Aged
Phenotype
CCR5 delta32
Gene expression profiling
Intensive Care Units
030104 developmental biology
Genetic marker
Case-Control Studies
030220 oncology & carcinogenesis
Host-Pathogen Interactions
biology.protein
Female
business
Subjects
Details
- ISSN :
- 15675769
- Volume :
- 98
- Database :
- OpenAIRE
- Journal :
- International Immunopharmacology
- Accession number :
- edsair.doi.dedup.....13eaadf6e3dd902791b6e7660154f257